|
The connection between Fosamax and osteonecrosis of the jaw was noticed as early as 2001. Several
recent studies published in medical journals confirm the connection between Fosamax and osteonecrosis.
Dr. Salvatore Ruggiero reviewed medical records of 63 patients who developed osteonecrosis
of the jaw between February 2001 and November 2003. Every one of these patients had taken bisphosphonates
for at least one year prior to developing the serious conditions.
The label for Fosamax minimizes the risk of osteonecrosis of the jaw in patients taking the
drug. The instructions provided to doctors prescribing Fosamax does not mention osteonecrosis
of the jaw in the section entitled "Warnings," instead listing it under a separate section
labeled "Precautions."
The risk for osteonecrosis of the jaw continues long after the patient stop taking Fosamax.
Some estimates indicate the risk can continue for as long as ten years once a patients discontinues
use of Fosamax. |
Fosamax: The Hiding of a Public Hazard
Law.com
October 5, 2006
Fosamax, Merck's Other Drug Problem
CNN
May 9, 2006
|
